Gapping down
In reaction to earnings/guidance:
- CGEN -9.8%, LHDX -7.9%, RIDE -7.1%, CPNG -4.4%, BEEM -4.3%, JAMF -4.3%, AZN -3.7%, GAN -3.2%, HYFM -3%, MCW -2%, ARRY -1.4% (also to acquire Soluciones Tecnicas Integrales Norland), PVG -0.8%, LAZR -0.7%
Other news:
- ONCR -33.1% (reports Initial Safety Tolerability Immune Activation and Positive Clinical Response Data from its Ongoing Phase 1 Clinical Study of ONCR-177)
- CBIO -32% (strategic decision to halt the clinical development of MarzAA report data to date and seek a buyer for its hemophilia assets)
- AFIB -24.6% (announces the initiation of AcQForce PFA-CE)
- ATHX -7% (reports updates on timing for Japan ARDS and stroke programs from Healios; Healios is targeting the filing of the application for this orphan regenerative medicine product for Q4 2021/Q1 2022.)
- NETI -6.9% (prices offering of 19.44 mln shares of common stock at $9.00 per share)
- TPST -5.9% (presents data supporting the dual mechanism of TPST-1495)
- ACET -5.6% (presents preclinical data for ADI-002 a GPC3-targeted development candidate for solid tumors)
- SCM -4.8% (stock offering)
- XLO -3.7% (preclinical data demonstrating anti-tumor activity and tolerability of XTX301)
- FBIO -2.8% (Journey Medical Corporation prices $35.2 mln IPO)
- IPHA -1.3% (highlights new NK cell engager data with partner Sanofi)
Analyst comments:
- FSM -2.8% (downgraded to Sell from Hold at Canaccord Genuity)
- EYE -2.6% (downgraded to Underperform from Buy at BofA Securities)
- CELH -2.1% (downgraded to Neutral from Outperform at Credit Suisse)
- GEF -1.4% (downgraded to Market Perform from Outperform at BMO Capital Markets)